BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/12/2024 9:30:57 AM | Browse: 154 | Download: 1067
 |
Received |
|
2024-06-10 13:04 |
|
Peer-Review Started |
|
2024-06-10 13:04 |
|
First Decision by Editorial Office Director |
|
2024-08-13 20:00 |
|
Return for Revision |
|
2024-08-14 23:36 |
|
Revised |
|
2024-09-02 13:16 |
|
Publication Fee Transferred |
|
2024-10-30 13:24 |
|
Second Decision by Editor |
|
2024-10-28 02:41 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-10-28 07:22 |
|
Articles in Press |
|
2024-10-28 07:22 |
|
Edit the Manuscript by Language Editor |
|
2024-11-11 05:16 |
|
Typeset the Manuscript |
|
2024-11-21 03:46 |
|
Publish the Manuscript Online |
|
2024-12-12 09:30 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhong-Xia Yang, Li-Ting Zhang, Xiao-Jun Liu, Xue-Bin Peng and Xiao-Rong Mao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Gansu Province |
No. 21JR7RA373 |
| Natural Science Foundation of Gansu Province |
No. 24JRRA295 |
|
| Corresponding Author |
Xiao-Rong Mao, Chief Physician, Department of Infectious Diseases, The First Hospital of Lanzhou University, No. 1 Donggangxi Road, Chengguan District, Lanzhou 730000, Gansu Province, China. layygrk@126.com |
| Key Words |
Interleukin-17A; Programmed death ligand-1; Interleukin-17A receptor; Small mothers against decapentaplegic 2; Hepatocellular carcinoma; Immunotherapy |
| Core Tip |
Over expression of programmed death ligand-1 (PD-L1) on tumor cells promote cancer immune escape through inhibiting T cell function. Interleukin-17A (IL-17A) can increase the expression of PD-L1 in tumor cells and promote tumor progression. However, related research in hepatocellular carcinoma (HCC) is scared. In this study, we clarified a novel mechanism that IL-17A upregulated PD-L1 expression in HCC cells by IL-17A receptor/phosphorylation-small mothers against decapentaplegic 2 axis. IL-17A could drive the immune escape of HCC cells. IL-17A also promoted the proliferation, migration, and angiogenesis of HCC cells, while inhibited the apoptosis of HCC cells. IL-17A inhibitor enhanced the therapeutic efficacy of PD-L1 antibody in HCC in vivo. |
| Publish Date |
2024-12-12 09:30 |
| Citation |
Yang ZX, Zhang LT, Liu XJ, Peng XB, Mao XR. Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 97831
|
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i1/97831.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i1.97831 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
